Biomarker panel diagnosis of thyroid cancer: A critical review

Expert Review of Anticancer Therapy

Volumn 8, Issue 9, 2008, Pages 1399-1413

  Griffith, Obi L ^a   Chiu, Connie G ^a   Gown, Allen M ^a   Jones, Steven J M ^a   Wiseman, Sam M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biomarker panel; Cancer; CK19; Cytokeratin 19; Diagnosis; Follicular; GAL3; Galectin 3; HBME 1; IHC; Immunohistochemistry; Neoplasm; Thyroid; Tissue microarray; TMA

Indexed keywords

ANDROGEN RECEPTOR; ARGINASE; AURORA A KINASE; BIOLOGICAL MARKER; CARRIER PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 19; FIBRONECTIN; GALECTIN 3; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HECTOR BATTIFORA MESOTHELIAL ANTIGEN 1; MONOCLONAL ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P16; SOLUTE CARRIER FAMILY 5 MEMBER 5; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ASPIRATION BIOPSY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; METHODOLOGY; PARATHYROID CARCINOMA; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID CANCER;

DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 55249108261     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.9.1399     Document Type: Review

References (65)

1. Gharib H, Papini E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol. Metab. Clin. North Am. 36(3), 707-735 (2007).
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83(12), 2638-2648 (1998).
3. Caraway NP, Sneige N, Samaan NA. Diagnostic pitfalls in thyroid fine-needle aspiration: a review of 394 cases. Diagn. Cytopathol. 9(3), 345-350 (1993).
4. Gharib H. Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. Mayo Clin. Proc. 69(1), 44-49 (1994).
5. Goellner JR, Gharib H, Grant CS, Johnson DA. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol. 31(5), 587-590 (1987).
6. Ravetto C, Colombo L, Dottorini ME. Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. Cancer 90(6), 357-363 (2000).
7. Baloch ZW, LiVolsi VA, Asa SL et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn. Cytopathol. 36(6), 425-437 (2008).
8. Gerhard R, da Cunha Santos G. Inter- and intraobserver reproducibility of thyroid fine needle aspiration cytology: an analysis of discrepant cases. Cytopathology 18(2), 105-111 (2007).
9. Baloch ZW, LiVolsi VA. Intraoperative assessment of thyroid and parathyroid lesions. Semin. Diagn. Pathol. 19(4), 219-226 (2002).
10. Wiseman SM, Baiiski C, Irvine R et al. Hemithyroidectomy: the optimal initial surgical approach for individuals undergoing surgery for a cytological diagnosis of follicular neoplasm. Ann. Surg. Oncol. 13(3), 425-432 (2006).
11. Melck A, Bugis S, Baliski C et al. Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. Am. J. Surg. 191(5), 593-597 (2006).
12. Fan J, Ren Y. Statistical analysis of DNA microarray data in cancer research. Clin. Cancer Res. 12(15), 4469-4473 (2006).
13. Quackenbush J. Microarray analysis and tumor classification. N. Engl. J. Med. 354(23), 2463-2472 (2006).
14. Akobeng AK. Understanding diagnostic tests 1: sensitivity, specificity and predictive values. Acta Paediatr. 96(3), 338-341 (2007).
15. Akobeng AK. Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice. Acta Paediatr. 96(4), 487-491 (2007).
16. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 96(5), 644-647 (2007).
17. Morey JS, Ryan JC, Van Dolah FM. Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR. Biol. Proced. Online 8, 175-193 (2006).
18. Ginestier C, Charafe-Jauffret E, Bertucci F et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am. J. Pathol. 161(4), 1223-1233 (2002).
19. Fu LM, Fu-Liu CS. Multi-class cancer subtype classification based on gene expression signatures with reliability analysis. FEBS Lett. 561(1-3), 186-190 (2004).
20. Vanguilder H, Vrana K, Freeman W. Twenty-five years of quantitative PCR for gene expression analysis. Bio Techniques 44(5), 619-626 (2008).
21. Griffith OL, Melck A, Jones SJ, Wiseman SM. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J. Clin. Oncol. 24(31), 5043-5051 (2006).
22. Fujarewicz K, Jarzab M, Eszlinger M et al. A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat. Cancer 14 (3), 809-826 (2007).
23. Rosen J, He M, Umbricht C et al. A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery 138(6), 1050-1056; discussion 1056-1057 (2005).
24. Kebebew E, Peng M, Reiff E, McMillan A. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer 106(12), 2592-2597 (2006).
25. Lubitz CC, Ugras SK, Kazam JJ et al. Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. J. Mol. Diagn. 8(4), 490-498; quiz 528 (2006).
26. Cerutti JM, Latini FR, Nakabashi C et al. Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin. Cancer Res. 12(11 Pt 1), 3311-3318 (2006).
27. Cerutti JM, Delcelo R, Amadei MJ et al. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J. Clin. Invest. 113(8), 1234-1242 (2004).
28. Riesco-Eizaguirre G, Santisteban P. Molecular biology of thyroid cancer initiation. Clin. Transl. Oncol. 9(11), 686-693 (2007).
29. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28(7), 742-762 (2007).
30. Kimura ET, Nikiforova, MN, Zhu Z et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63(7), 1454-1457 (2003).
31. Kroll TG, Sarraf P, Pecciarini L et al. PAX8-PPARγ 1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289(5483), 1357-1360 (2000).
32. Giordano TJ, Kuick R, Thomas DG et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/ PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24(44), 6646-6656 (2005).
33. Visone R, Pallante P, Vecchione A et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26(54), 7590-7595 (2007).
34. Walker RA. Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment I. Histopathology 49(4), 406-410 (2006).
35. Bertheau P, Cazals-Hatern D, Meignin V et al. Variability of immunohistochemical reactivity on stored paraffin slides. J. Clin. Pathol. 51(5), 370-374 (1998).
36. Kashima K, Yokoyama S, Daa T et al. Cytoplasmic biotin-like activity interferes with immunohistochemical analysis of thyroid lesions: a comparison of antigen retrieval methods. Mod. Pathol. 10(5), 515-519 (1997).
37. Bussolati G, Gugliotta P, Volante M, Pace M, Papotti M. Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology 31(5), 400-407 (1997).
38. Kim SH, Jung KC, Shin YK et al. The enhanced reactivity of endogenous biotin-like molecules by antigen retrieval procedures and signal amplification with tyramine. Histochem. J. 34 (3-4), 97-103 (2002).
39. Barondes SH, Castronovo V, Cooper DN et al. Galectins: a family of animal β-galactoside-binding lectins. Cell 76(4), 597-598 (1994).
40. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat. Rev Cancer 5(1), 29-41 (2005).
41. Sheibani K, Esteban JM, Bailey A, Battifora H, Weiss LM. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothellioma. Hum. Pathol. 23(2), 107-116 (1992).
42. Gumurdulu D, Zeren EH, Cagle PT et al. Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages. Pathol. Oncol. Res. 8(3), 188-193 (2002).
43. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Hispathology 48(3), 223-232 (2006).
44. Moll R. Cytokeratins in the histological diagnosis of malignant tumors. Int. J Biol. Markers 9(2), 63-69 (1994).
45. Segev DL, Clark DP, Zeiger MA, Umbricht C. Beyond the suspicious thyroid fine needle aspirate. A review. Acta Cytol. 47(5), 709-722 (2003).
46. de Maros PS, Ferreira AP, de Oliveira Facuri F et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47(4), 391-401 (2005).
47. Barroeta JE, Baloch ZW, Lai P et al. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr. Pathol. 17(3), 225-234 (2006).
48. kip1 in the differential diagnosis of thyroid nodules. J. Korean Med. Sci. 22(4), 621-628 (2007).
49. Scogtamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am. J. Clin. Pathol. 126(5), 700-708 (2006).
50. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod. Pathol. 19(12), 1631-1637 (2006).
51. Rossi ED, Raffaelli M, Mule A et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 48(7), 795-800 (2006).
52. Wiseman SM, Melck A, Masoudi H et al. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann. Sorg. Oncal. (2008) (Epub ahead of print).
53. Nasser SM, Pitman MB, Pilch BZ, Faquin WC. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining. Cancer 90(5), 307-311 (2000).
54. Sanabria A, Carvaiho AL, Piana de Andrade V et al. Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of "follicular neoplasm"? A critical appraisal of the evidence. Head Neck 29(11), 1046-1054 (2007).
55. de Micco C, Savchenko, V, Giorgi R, Sebag F, Henry JF. Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxiclase and dipeptidyl aminopeptidase IV, Br. J. Cancer 98(4), 818-823 (2008).
56. Liu YY, Morreau H, Klevit J et al. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-γ, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur. J. Endocrinol. 158(3), 375-384 (2008).
57. Prasad ML, Pellegata NS, Huang Y et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod. Pathol 18(1), 48-57 (2005).
58. Nakamura N, Erickson LA, Jin L et al. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr. Pathol. 17(3), 213-223 (2006).
59. Bhanot P, Yang J, Schnadig VJ, Logrono R. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature. Diagn. Cytopathol. 35(5), 285-292 (2007).
60. Wiseman SM, Griffith OL, Deen S et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch. Surg. 142(8), 717-727; discussion 727-719 (2007).
61. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Son [Ser. B] 57(1), 289-300 (1995).
62. Pounds SB. Estimation and control of multiple testing error rates for microarray studies. Brief Bioinform. 70), 25-36 (2006).
63. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin. Oncol. 25 (1), 118-145 (2007).
64. Bartolazzi A, Gasbarri A, Papotti M et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357(9269), 1644-1650 (2001).
65. Bartolazzi A, Orlandi F, Saggiorato E et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 9(6), 543-549 (2008).